metformin has been researched along with exenatide in 194 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 44 (22.68) | 29.6817 |
| 2010's | 119 (61.34) | 24.3611 |
| 2020's | 31 (15.98) | 2.80 |
| Authors | Studies |
|---|---|
| Washburn, WN | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Baron, AD; Bicsak, TA; Fineman, MS; Gaines, E; Kim, D; Shen, LZ; Taylor, K; Varns, A | 1 |
| Baron, AD; Fineman, MS; Kendall, DM; Kim, DD; Riddle, MC; Rosenstock, J; Zhuang, D | 1 |
| Baron, AD; DeFronzo, RA; Fineman, MS; Han, J; Kim, DD; Ratner, RE | 1 |
| Abramowicz, M; Zuccotti, G | 1 |
| Keating, GM | 1 |
| Bicsak, TA; Brodows, RG; Kim, DD; Maggs, D; Nielsen, LL; Poon, T; Ratner, RE; Stonehouse, AH; Zhang, B | 1 |
| Blonde, L; Han, J; Kendall, DM; Kim, DD; Klein, EJ; Mac, SM; Poon, TH; Taylor, KL; Trautmann, ME; Zhang, B | 1 |
| Baker, DE; Iltz, JL; Keith Campbell, R; Setter, SM | 1 |
| Bunck, MC; Diamant, M; Heine, RJ; Pouwels, PJ; Tushuizen, ME; van Waesberghe, JH | 1 |
| Göke, B | 1 |
| Brodows, R; Duran, S; Festa, A; Johns, D; Kim, D; Nauck, MA; Northrup, J; Trautmann, M | 1 |
| DeFronzo, RA; Ferrannini, E; Halseth, A; Mari, A; Nanayakkara, N; Nielsen, LL | 1 |
| Erdmann, E; Reuter, H | 1 |
| Bowlus, CL; Buse, JB; Guan, X; Holcombe, JH; Klonoff, DC; Maggs, DG; Nielsen, LL; Wintle, ME | 1 |
| Home, PD | 1 |
| Brodows, RG; Durán García, S; Giaconia, JM; Hoogwerf, BJ; Kim, DD; Milton, DR; Trautmann, ME; Zinman, B | 1 |
| Malozowski, S | 1 |
| Cvetković, RS; Plosker, GL | 1 |
| Whitehill, D | 1 |
| Fineman, M; Guan, X; Nelson, P; Poon, T; Schnabel, C; Wintle, M | 1 |
| Mirza, SA | 1 |
| Barnett, AH; Brodows, R; Burger, J; Johns, D; Kendall, DM; Roberts, A; Trautmann, ME | 1 |
| Bergenstal, RM; Brodows, R; Gates, JR; Glass, LC; Kim, D; Lenox, S; Qu, Y; Trautmann, M | 1 |
| Halperin, F; Ingelfinger, JR; McMahon, GT | 1 |
| Aronne, LJ; Neff, LM | 1 |
| Bhushan, M; Bhushan, R; Elkind-Hirsch, K; Marrioneaux, O; Vernor, D | 1 |
| Doggrell, SA | 1 |
| Barnett, A; Rahim, A; Samat, A | 1 |
| Fabreegas, B | 1 |
| Brodows, R; Chuang, LM; Gao, Y; Jang, HC; Johns, D; Mohan, V; Ning, G; Northrup, J; Shah, S; Wu, TJ; Yoon, KH | 1 |
| Bunck, MC; Cornér, A; Deng, W; Diamant, M; Eliasson, B; Heine, RJ; Kendall, DM; Malloy, JL; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H | 1 |
| Bailey, T; Bergenstal, R; Chang, D; Gylvin, T; Lewin, A; Roberts, V | 1 |
| Arnold Chan, K; Dore, DD; Seeger, JD | 1 |
| Basha, S; Jain, R; Ramachandran, A; Shetty, S; Tripathy, NR | 1 |
| Brodows, R; Cox, DJ; Crean, J; Johns, D; Kovatchev, B; McCall, AL | 1 |
| Hamdy, O; Mitri, J | 1 |
| Gallwitz, B; Guzmán, JR; Kazda, C; Kraus, P; Nicolay, C; Rose, L; Schernthaner, G; Simó, R | 1 |
| DeFronzo, RA; Glass, LC; Lewis, MS; Maggs, D; Qu, Y; Triplitt, C | 1 |
| Brown, A; Desai, M; Taneja, D; Tannock, LR | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Franzetti, IG; Gadaleta, G; Maffioli, P; Piccinni, MN; Querci, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Arnolds, S; Clair, J; Dain, MP; Dellweg, S; Kapitza, C; Nauck, MA; Rave, K | 1 |
| Freeman, JS | 2 |
| Kress, S | 1 |
| Bergenstal, RM; Macconell, L; Malloy, J; Malone, J; Porter, LE; Walsh, B; Wilhelm, K; Wysham, C; Yan, P | 1 |
| Meier, JJ; Nauck, MA | 2 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 5 |
| Cao, D; Liutkus, J; Northrup, J; Norwood, P; Pop, L; Rosas Guzman, J; Trautmann, M | 1 |
| Al-Jebawi, AF | 1 |
| Bergenstal, RM; Buse, JB; Glass, LC; Heilmann, CR; Hoogwerf, BJ; Kwan, AY; Lewis, MS; Rosenstock, J | 1 |
| Conner, C; Hammer, M; Lee, WC | 1 |
| Bachmann, O; Becker, B; Böhmer, M; Gallwitz, B; Helsberg, K; Milek, K; Mölle, A; Peters, N; Petto, H; Segiet, T | 1 |
| Bergenstal, R; Malloy, J; Malone, J; Taylor, K; Walsh, B; Wysham, C; Yan, P | 1 |
| Bonaventura, A; Bossi, AC; Derosa, G; Fogari, E; Franzetti, IG; Guazzini, B; Maffioli, P; Putignano, P; Querci, F; Testori, G | 1 |
| Buysschaert, M; de la Tribonnière, X; Hermans, MP; Oriot, P; Selvais, P | 1 |
| Bajaj, M; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P | 1 |
| Heller, C; Kühn, MC; Mülders-Opgenoorth, B; Scherbaum, WA; Schinner, S; Schott, M; Willenberg, HS | 1 |
| Bunck, MC; Cornér, A; Diamant, M; Eliasson, B; Heine, RJ; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H | 1 |
| Drucker, DJ | 1 |
| Bajaj, M; Chan, L; Gonzalez, EV; Gutierrez, A; Jogi, M; Krishnamurthy, R; Muthupillai, R; Samson, SL; Sathyanarayana, P | 1 |
| Adam, P; Dudziak, K; Horger, M; Müssig, K; Neumann, H; Rettig, I | 1 |
| Jermendy, G | 1 |
| Bray, GA; Ryan, DH | 1 |
| Ferrer Gómez, M; García Zafra, MV; Hellín Gil, MD; Pujante Alarcón, P; Román, LM; Tébar Massó, J | 1 |
| Boardman, MK; Chan, M; Cuddihy, RM; González, JG; Hanefeld, M; Kumar, A; Russell-Jones, D; Wolka, AM | 1 |
| Butler, PC; Dawson, D; Dry, SM; Gier, B; Kirakossian, D; Matveyenko, AV | 1 |
| Bachmann, OP; Chan, JY; Lüdemann, J; Oliveira, JH; Reed, VA; Violante, R; Yoon, KH; Yu, MB | 1 |
| Corsi, A; Ponzani, P | 1 |
| Nauck, MA | 1 |
| Kuritzky, L | 1 |
| Carbone, A; Ciccarelli, L; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 2 |
| Faludi, P; Fövényi, J; Han, J; Iványi, T; Kiljanski, J; Macconell, L; Wille, S | 1 |
| Bank, AJ; Bergenstal, RM; Gonzalez-Campoy, JM; Katz, H; Kelly, AS | 1 |
| Basson, BR; Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Guzman, J; Kiljański, J; Sapin, H; Schernthaner, G; Simó, R; Trautmann, M | 1 |
| Frier, BM; Inkster, B; Zammitt, NN | 1 |
| Carallo, C; De Luca, S; Gnasso, A; Irace, C; Loprete, A; Scavelli, F; Shehaj, E | 1 |
| Gao, Y; Guo, XH; Huang, YY; Song, WL; Yuan, GH | 1 |
| Flaherty, AM | 1 |
| Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME | 1 |
| Bergenstal, RM; Han, J; Li, Y; Porter, TK; Weaver, C | 1 |
| Bhavsar, S; Cherrington, A; Mudaliar, S | 1 |
| Adetunji, O; Davies, M; Heller, S; Sapin, H; Sreenan, S; Tahbaz, A; Vora, J | 1 |
| Chen, S; Grimm, M; Wysham, C | 1 |
| Karagianni, P; Kartali, N; Polyzos, SA; Sambanis, C; Zografou, I | 1 |
| Alessi, TR; Baron, MA; Henry, RR; Logan, DK; Luskey, K; Rosenstock, J | 1 |
| Moniri, NH; Ryan, GJ; Smiley, DD | 1 |
| Cho, YM; Kang, GH; Oh, TJ; Park, KS; Shin, JY | 1 |
| Huang, Q; Peng, Y; Wang, Y; Zhao, L | 1 |
| Balas, B; Balena, R; Boldrin, M; Bolli, GB; Charbonnel, B; Gastaldelli, A; Ratner, R; Rosenstock, J | 1 |
| Bailey, T | 1 |
| Lüdemann, J | 1 |
| Carbone, A; Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Querci, F | 1 |
| Blase, E; Brunell, SC; Grimm, M; Li, Y | 1 |
| Lenart-Lipińska, M; Matyjaszek-Matuszek, B; Nowakowski, A; Rogalska, D | 1 |
| Behera, BN; Bhansali, A; Gangadhar, P; Gupta, R; Palikhe, G; Sachdeva, N | 1 |
| Fan, H; Pan, Q; Xu, Y; Yang, X | 1 |
| Bi, Y; Dai, YY; Feng, WH; Hu, J; Hu, Y; Li, P; Liu, YQ; Shao, LL; Shen, SM; Tong, GY; Wang, WM; Xiang, SK; Yang, DH; Yuan, XW; Zhu, DL | 1 |
| Arakaki, R; Atisso, C; Blevins, T; Colon, G; Garcia, P; Kuhstoss, D; Lakshmanan, M; Wysham, C | 1 |
| Beiroa, D; Dieguez, C; Escalada, J; Fernø, J; Frühbeck, G; Gallego, R; Herranz, D; Imbernon, M; Lopez, M; Nogueiras, R; Salvador, J; Senra, A; Serrano, M; Villarroya, F | 1 |
| Cleall, S; de Vries, D; Diamant, M; Hoogwerf, BJ; MacConell, L; Malone, JK; Nauck, MA; Reaney, M; Shaginian, R; Wolffenbuttel, BH | 1 |
| Chen, JH; Lee, CH; Tang, WH | 1 |
| Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP | 1 |
| Buse, JB; Diamant, M; Donsmark, M; Furber, S; Han, J; MacConell, L; Maggs, D; Peters, A; Russell-Jones, D | 1 |
| Ekoé, JM; Kuritzky, L; Landó, LF; Mancillas-Adame, L; Umpierrez, G | 1 |
| Abdul-Ghani, MA; Adams, J; Cersosimo, E; DeFronzo, RA; Maggs, D; Puckett, C; Triplitt, C | 1 |
| Bueno, M; Lecube, A; Suárez, X | 1 |
| Thompson, AM; Trujillo, JM | 1 |
| Barb, D; Duva, IM; He, Q; Jackson, SL; Long, Q; Olson, DE; Phillips, LS; Rhee, MK; Tomolo, AM; Yong, C | 1 |
| Dotta, F; Festa, A; Gallwitz, B; Guerci, B; Kiljański, J; Rosas-Guzmán, J; Schernthaner, G; Simó, R; Zhou, M | 2 |
| Dolan, JG; Joy, SM; Maruthur, NM; Shihab, HM; Singh, S | 1 |
| Bergenstal, R; Branch, KR; Davis, B; Hirsch, I; Khakpour, D; Kingry, C; O'Brien, K; Pressel, S; Probstfield, JL; Riddle, M | 1 |
| Lakshmanan, M; Pechtner, V; Reaney, M; van Brunt, K; Yu, M | 1 |
| Ge, SQ; Tao, X; Zhang, B; Zhang, EH; Zhang, X | 1 |
| Dungan, KM; Fahrbach, JL; Raz, I; Sealls, W; Skrivanek, Z | 1 |
| Athanasiadou, E; Bekiari, E; Boura, P; Karagiannis, T; Liakos, A; Mainou, M; Matthews, DR; Paschos, P; Rika, M; Tsapas, A; Vasilakou, D | 1 |
| Hamaguchi, Y; Kawanami, T; Motonaga, R; Murase, K; Nomiyama, T; Tanabe, M; Tanaka, T; Terawaki, Y; Tsutsumi, Y; Yanase, T | 1 |
| Solis-Herrera, C; Triplitt, C | 1 |
| Tong, N; Zhang, L; Zhang, M; Zhang, Y | 1 |
| Bi, Y; Feng, W; Ji, C; Jin, L; Li, P; Shen, S; Sun, L; Zhu, D | 1 |
| García Díaz, E; Godoy, T; Guagnozzi, D; Gutiérrez, V; Larrañaga, Y; Maza, C; Mendoza, C; Perdomo, D; Taleb, G | 1 |
| Cavun, S; Guclu, M; Gul, Z; Kisakol, G; Kiyici, S; Sigirli, D; Topyildiz, F | 1 |
| Chung, BH; Jin, J; Jin, L; Lim, SW; Yang, CW | 1 |
| Fox, CK; Gross, AC; Kelly, AS; Rudser, KD; Ryder, JR | 1 |
| Li, Y; Liu, G; Liu, S; Tian, M; Wang, Y; Zhang, X | 1 |
| Li, ZX; Sun, F; Wu, SS; Yang, ZR; Zhan, SY | 1 |
| Bołdys, A; Bułdak, RJ; Bułdak, Ł; Machnik, G; Okopień, B; Łabuzek, K | 1 |
| de Lapertosa, SB; Frechtel, G; Hardy, E; Sauque-Reyna, L | 1 |
| Diamant, M; Hoekstra, T; Kramer, MH; Muskiet, MH; Smits, MM; Tonneijck, L; van Raalte, DH | 1 |
| Abd El Aziz, MS; Bettge, K; Kahle, M; Meier, JJ; Nauck, MA | 1 |
| Gadde, KM; Hardy, E; Iqbal, N; Öhman, P; Vetter, ML | 1 |
| Anglin, G; Barkin, JS; Frossard, JL; Harper, KD; Hensley, IE; Milicevic, Z; Nauck, MA | 1 |
| Hemmingsen, B; Metzendorf, MI; Richter, B; Sonne, DP | 1 |
| Chen, Y; Cui, Y; Fang, Y; Guo, X; Ji, L; Lou, K; Wang, Q; Wang, Y; Xu, B; Xu, L; Zhao, X; Zhu, L | 1 |
| Adanichkin, N; Campbell, JM; Kurmis, R; Munn, Z | 1 |
| Alessi, T; Baron, M; Carls, G; Henry, R; McCarthy, JF; Rosenstock, J; Yee, J | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Öhman, P | 1 |
| Du, X; Hu, C; Lu, W; Lu, Z; Shao, X; Shi, B | 1 |
| Ahmed, A; Frías, JP; Guja, C; Hardy, E; Jabbour, S; Öhman, P; Wang, H | 1 |
| Hao, M; Kuang, HY; Li, BW; Ma, XF; Pan, J; Shao, N; Wu, WH; Yu, XY; Yu, YM; Zhang, HJ | 1 |
| Dunham, MW; Hurren, KM | 1 |
| Chen, SH; Liu, XN; Peng, Y; Sun, QY | 1 |
| Chen, H; Gong, Y; Lin, R; Liu, E; Liu, X; Long, T; Mai, T; Shen, H; Wang, F; Xie, Y; Zhang, Y; Zheng, S; Zheng, Y | 1 |
| Fan, R; Gao, J; Jiang, C; Kang, Z; Lin, S; Yin, D; Zeng, J; Zhang, T | 1 |
| Bi, Y; Qing, Z; Wang, X; Yang, QX; Zhang, B; Zhang, W; Zhang, X; Zhang, Z; Zhu, D | 1 |
| Aglialoro, A; Albanese, V; Albertelli, M; Boschetti, M; Ferone, D; Gatto, F; Minuto, M; Monachesi, M; Talco, M; Teti, C; Viviani, G | 1 |
| Cai, L; Chen, L; Deng, X; Ge, S; Tao, X | 1 |
| Blazina, I; Selph, S | 1 |
| Emery, A; Retnakaran, R | 1 |
| Gao, Y; Guo, L; Hong, T; Li, Q; Tian, Q; Xiao, W; Yang, J; Zhong, L | 1 |
| Ahmed, AAM; Khodeer, DM; Moustafa, YM; Saad, ZA; Zaitone, SA | 1 |
| Hong, SW; Kim, MJ; Kwon, H; Lee, J; Lee, WY; Park, SE; Rhee, EJ | 1 |
| Ahmed, A; Choi, J; Frías, JP; Guja, C; Hardy, E; Jabbour, SA; Sjöström, CD | 1 |
| Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC | 1 |
| Hong, T; Tian, Q; Wang, C; Wang, H; Wei, R; Xiao, W; Yang, J; Yang, K | 1 |
| Bastian, M; Brath, H; Harreiter, J; Just, I; Kautzky-Willer, A; Klepochova, R; Krššák, M; Leutner, M; Schelkshorn, C | 1 |
| Chen, X; Duan, Y; He, W; Hu, J; Hu, S; Li, W; Liao, Y; Lin, M; Liu, L; Liu, P; Liu, Z; Ma, J; Shao, S; Shen, L; Xu, Y; Xue, Y; Yin, P; Yu, X; Zeng, J; Zeng, Z; Zhang, J; Zhao, S; Zhao, T | 1 |
| Fu, BY; Wang, XJ | 1 |
| Davis, SN; Siamashvili, M | 1 |
| Bellanger, D; Chappell, N; Elkind-Hirsch, KE; Seidemann, E; Storment, J | 1 |
| He, B; Li, X; Lv, B; Wang, D; Xing, C; Zhao, H | 1 |
| Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N | 1 |
| Deng, Y; Ding, XS; Ma, RL; Sun, AJ; Wang, YF; Zhu, SY | 1 |
| Abdelgani, S; Abdul-Ghani, M; Adams, J; Alatrach, M; Alkhouri, N; Cersosimo, E; Clarke, GD; DeFronzo, RA; Gastaldelli, A; Lavynenko, O; Li, J; Puckett, C; Triplitt, C; Vasquez, JA | 1 |
| Akarsu, E; Balci, SO; Bozdag, Z; Demirel, C; Korkmaz, M; Lule, KO; Lule, NO; Sayiner, ZA; Yilmaz, I | 1 |
| Al-Abdulrazzaq, D; Bishai, R; Carter, D; Doehring, O; Geller, D; Karoly, E; Monyak, J; Shehadeh, N; Sjöström, CD; Tamborlane, WV; Troja, T; Vazquez, EM | 1 |
| Abdul-Ghani, MA; Adams, AC; Adams, J; Cersosimo, E; Cheng, CC; DeFronzo, RA; Fourcaudot, M; Heikkinen, S; Khattab, A; Norton, L; Puckett, C; Samms, RJ; Triplitt, C; Tsintzas, K | 1 |
| Chapple, S; Kennard, MR; King, AJ; Nandi, M | 1 |
| Li, R; Mai, T; Zhang, Y; Zheng, S | 1 |
| Feng, Y; Ge, Y; He, Y; Hou, L; Huo, M; Ji, Y; Li, H; Liu, X; Liu, Y; Luo, Q; Qian, F; Wang, J; Wei, Y; Wu, S; Wu, Y; Xue, F; Yu, Y | 1 |
| Liu, H; Wu, F; Xie, Y; Yin, S; Zhang, Q; Zhao, G | 1 |
| Akarsu, E; Balcı, SO; Bozdag, Z; Demirel, C; Korkmaz, M; Sayiner, ZA; Yılmaz, I | 1 |
| Agcakaya, E; Erbakan, A; Mutlu, HH; Sargin, M | 1 |
| Liao, N; Wen, SH; Yan, CQ; Ye, ZR | 1 |
| Chen, J; Deng, Y; Ding, XS; Gan, J; Ma, RL; Sun, AJ; Zhu, SY | 1 |
| Chen, J; Gu, H; Hu, J; Li, M; Xie, Z | 1 |
| Wu, Y; Yuan, S | 1 |
| Guo, Y; Hamiti, S; Hu, Y; Ma, Y; Song, X; Wang, X; Yusufu, M; Zhang, K | 1 |
42 review(s) available for metformin and exenatide
| Article | Year |
|---|---|
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Evaluation, Preclinical; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors | 2009 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Peptides; Sulfonylurea Compounds; Venoms | 2006 |
[Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus].
Topics: Amino Acid Sequence; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Exenatide; Gastric Emptying; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Receptors, Glucagon; Sulfonylurea Compounds; Venoms | 2007 |
Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea).
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Peptides; Sulfonylurea Compounds; Venoms | 2007 |
Pharmacotherapy for obesity.
Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclobutanes; Exenatide; Gastrointestinal Hormones; Humans; Islet Amyloid Polypeptide; Lactones; Leptin; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Venoms | 2007 |
Pharmacotherapy for obesity in menopausal women.
Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Lactones; Menopause; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Venoms | 2008 |
Diabetes medications and body weight.
Topics: Abdominal Fat; Benzamides; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Exenatide; Glucagon-Like Peptide 1; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Insulin; Metformin; Obesity; Peptides; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Gain; Weight Loss | 2009 |
Managing highly insulin-resistant diabetes mellitus: weight loss approaches and medical management.
Topics: Amyloid; Bariatric Surgery; Diabetes Mellitus; Diet, Reducing; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Exercise; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Islet Amyloid Polypeptide; Liraglutide; Metformin; Obesity; Peptides; Thiazolidinediones; Treatment Failure; Venoms; Weight Loss | 2010 |
Optimizing outcomes for GLP-1 agonists.
Topics: Algorithms; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
The design of the liraglutide clinical trial programme.
Topics: Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pyrazines; Randomized Controlled Trials as Topic; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
Drug-induced hypoglycaemia in type 2 diabetes.
Topics: Adamantane; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Humans; Hypoglycemia; Hypoglycemic Agents; Metformin; Peptides; Pharmacogenetics; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2012 |
Management of diabetes and pancreatic cancer.
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus, Type 2; Disease Management; Drug Resistance; Drug Therapy, Combination; Exenatide; Fluorouracil; Humans; Hyperglycemia; Hyperglycemic Hyperosmolar Nonketotic Coma; Hypoglycemic Agents; Insulin; Leucovorin; Male; Malnutrition; Metformin; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Peptides; Sulfonylurea Compounds; Venoms | 2012 |
Evolution of exenatide as a diabetes therapeutic.
Topics: Animals; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, Knockout; Models, Animal; Nausea; Peptides; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2013 |
Once weekly exenatide: efficacy, tolerability and place in therapy.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diarrhea; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Male; Metformin; Middle Aged; Nausea; Peptides; Randomized Controlled Trials as Topic; Treatment Outcome; Venoms; Vomiting; Weight Loss | 2013 |
Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.
Topics: Blood Glucose; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2013 |
Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
Topics: Algorithms; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Metformin; Peptides; Piperidines; Practice Guidelines as Topic; Receptors, Glucagon; Sulfonylurea Compounds; Thiazolidinediones; Venoms | 2013 |
[Treatment of type 2 diabetes mellitus--which role do GLP-1 receptor agonists play?].
Topics: Blood Glucose; Clinical Trials as Topic; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combination; Exenatide; Exercise; Germany; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Guideline Adherence; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Peptides; Receptors, Glucagon; Treatment Failure; Venoms | 2011 |
Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2014 |
[Twice-daily and weekly exenatide: clinical profile of two pioneer formulations in incretin therapy].
Topics: Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Female; Gastrointestinal Diseases; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Peptides; Pioglitazone; Receptors, Glucagon; Thiazolidinediones; Venoms; Weight Loss | 2014 |
Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Pioglitazone; Pyrazines; Receptors, Glucagon; Recombinant Fusion Proteins; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2015 |
Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once-weekly dulaglutide AWARD programme.
Topics: Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Liraglutide; Male; Metformin; Middle Aged; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms; Weight Gain | 2016 |
Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Incretins; Male; Metformin; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Venoms | 2015 |
GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Topics: Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Peptides; Recombinant Fusion Proteins; Risk Factors; Venoms | 2015 |
Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Glargine; Liraglutide; Metformin; Patient Safety; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Sitagliptin Phosphate; Treatment Outcome; Venoms | 2016 |
Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations.
Topics: Anti-Obesity Agents; Body Mass Index; Child; Directive Counseling; Exenatide; Humans; Hypoglycemic Agents; Metformin; Pediatric Obesity; Peptides; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Venoms; Weight Loss | 2016 |
[Impact of glucagon-like peptide-1 receptor agonists on nasopharyngitis and upper respiratory tract infection among patients with type 2 diabetes: a network meta-analysis].
Topics: Bayes Theorem; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Liraglutide; Metformin; Nasopharyngitis; Peptides; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Respiratory Tract Infections; Thiazolidinediones; Venoms | 2016 |
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diarrhea; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Nausea; Peptides; Venoms; Vomiting | 2017 |
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Metformin; Nitriles; Peptides; Pyrrolidines; Randomized Controlled Trials as Topic; Risk Factors; Venoms; Vildagliptin | 2017 |
Intensive insulin therapy, insulin sensitisers and insulin secretagogues for burns: A systematic review of effectiveness and safety.
Topics: Burns; Dipeptidyl-Peptidase IV Inhibitors; Disease Management; Exenatide; Glipizide; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Metformin; Pioglitazone; Rosiglitazone; Secretagogues; Sulfonylurea Compounds | 2018 |
Understanding the impact of commonly utilized, non-insulin, glucose-lowering drugs on body weight in patients with type 2 diabetes.
Topics: Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucosides; Humans; Hypoglycemic Agents; Metformin; Peptides; Sodium-Glucose Transporter 1; Venoms | 2018 |
Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Exenatide; Female; Glyburide; Humans; Male; Metformin; Network Meta-Analysis; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Sulfonylurea Compounds; Vildagliptin | 2019 |
Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Topics: Blood Glucose; Body Weight; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone | 2019 |
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
Topics: Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Heart Disease Risk Factors; Humans; Hypoglycemic Agents; Insulin Resistance; Liraglutide; Metformin; Polycystic Ovary Syndrome; Weight Loss | 2021 |
Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Insulin; Insulin Resistance; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic | 2022 |
Comparative efficacy and safety of glucose-lowering drugs in children and adolescents with type 2 diabetes: A systematic review and network meta-analysis.
Topics: Adolescent; Adult; Child; Diabetes Mellitus, Type 2; Exenatide; Glucose; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Metformin; Network Meta-Analysis; Sitagliptin Phosphate | 2022 |
Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Anti-Obesity Agents; Child; Exenatide; Humans; Liraglutide; Metformin; Obesity; Orlistat; Topiramate; Weight Loss | 2022 |
The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Exenatide; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate; Randomized Controlled Trials as Topic | 2023 |
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Topics: Body Weight; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Metformin | 2023 |
Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Topics: Body Mass Index; Comorbidity; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; East Asian People; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Quality-Adjusted Life Years; Treatment Outcome | 2023 |
Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.
Topics: Exenatide; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Rate | 2023 |
78 trial(s) available for metformin and exenatide
| Article | Year |
|---|---|
Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Fructosamine; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Islets of Langerhans; Lipids; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2003 |
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms | 2005 |
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Peptides; Proinsulin; Venoms | 2005 |
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Overweight; Peptides; Risk Factors; Venoms; Weight Loss | 2006 |
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Overweight; Peptides; Risk Factors; Sulfonylurea Compounds; Venoms; Weight Loss | 2006 |
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms | 2007 |
Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Models, Theoretical; Peptides; Placebos; Postprandial Period; Sulfonylurea Compounds; Venoms | 2006 |
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Liver Function Tests; Male; Metformin; Middle Aged; Obesity; Peptides; Sulfonylurea Compounds; Venoms; Weight Loss | 2007 |
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Injections, Subcutaneous; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nausea; Peptides; Thiazolidinediones; Venoms; Vomiting; Weight Loss | 2007 |
The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pilot Projects; Placebos; Venoms | 2007 |
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Topics: Adult; Blood Glucose; Body Weight; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Resistance; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Peptides; Sulfonylurea Compounds; Venoms | 2007 |
Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Glycemic Index; Humans; Hypoglycemic Agents; Insulin; Life Style; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms; Weight Gain; Weight Loss | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menstruation; Metformin; Overweight; Peptides; Polycystic Ovary Syndrome; Sex Hormone-Binding Globulin; Venoms | 2008 |
Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea.
Topics: Asian People; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms | 2009 |
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Topics: Arginine; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Secretion; Insulin-Secreting Cells; Insulin, Long-Acting; Kinetics; Male; Metformin; Middle Aged; Peptides; Venoms | 2009 |
Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
Topics: Adult; Biphasic Insulins; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin, Isophane; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms | 2009 |
Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Venoms; Weight Gain | 2010 |
Exenatide versus glibenclamide in patients with diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Exenatide; Female; Glyburide; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Proinsulin; Resistin; Retinol-Binding Proteins, Plasma; Venoms; Young Adult | 2010 |
Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Venoms | 2010 |
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial.
Topics: Blood Pressure; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Computer-Assisted; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipid A; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nausea; Peptides; Placebos; Thiazolidinediones; Treatment Outcome; Venoms; Vomiting | 2010 |
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Sensitivity and Specificity; Thiazolidinediones; Venoms | 2011 |
Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Aspart; Metformin; Middle Aged; Peptides; Treatment Outcome; Venoms | 2011 |
DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2011 |
Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Inflammation; Insulin Resistance; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms | 2011 |
Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Aspartate Aminotransferases; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Fasting; Fatty Acids, Nonesterified; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liver; Magnetic Resonance Spectroscopy; Metformin; Middle Aged; Obesity; Peptides; Pioglitazone; PPAR gamma; Receptors, Glucagon; Thiazolidinediones; Triglycerides; Venoms | 2011 |
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Venoms | 2011 |
Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Topics: Adult; Aged; Animals; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Edema; Exenatide; Fatty Liver; Female; Fibroblast Growth Factors; Humans; Hypoglycemic Agents; Liver; Lower Extremity; Male; Metformin; Mice; Middle Aged; Nausea; Non-alcoholic Fatty Liver Disease; Obesity; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2011 |
[Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
Topics: Adult; Aged; Anti-Obesity Agents; Antihypertensive Agents; Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gastric Emptying; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Nausea; Obesity; Peptides; Satiety Response; Treatment Outcome; Venoms; Vomiting; Weight Loss; Young Adult | 2012 |
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Venoms | 2012 |
A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sitaglipti
Topics: Adolescent; Adult; Aged; Argentina; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Germany; Glycated Hemoglobin; Greece; Humans; Hypoglycemia; Hypoglycemic Agents; India; Male; Metformin; Mexico; Middle Aged; Peptides; Pyrazines; Republic of Korea; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms | 2012 |
Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
Topics: Adiponectin; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Tumor Necrosis Factor-alpha; Venoms; Weight Loss | 2012 |
Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Humans; Hungary; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms | 2012 |
Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial.
Topics: Aged; Analysis of Variance; Biomarkers; Blood Glucose; C-Reactive Protein; Endothelium, Vascular; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperemia; Hypoglycemic Agents; Inflammation Mediators; Lipoproteins, LDL; Male; Metformin; Microcirculation; Middle Aged; Obesity, Abdominal; Peptides; Prediabetic State; Time Factors; Treatment Outcome; Upper Extremity; Vascular Cell Adhesion Molecule-1; Venoms | 2012 |
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Risk Factors; Sulfonylurea Compounds; Treatment Failure; Venoms; Young Adult | 2012 |
Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research.
Topics: Aged; Blood Flow Velocity; Brachial Artery; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrocardiography; Endothelium, Vascular; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Receptors, Glucagon; Sulfonylurea Compounds; Ultrasonography, Doppler; Vasodilation; Venoms | 2013 |
Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study.
Topics: Adult; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Nausea; Obesity; Peptides; Venoms; Weight Loss | 2012 |
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Receptors, Glucagon; Rosiglitazone; Thiazolidinediones; Venoms | 2012 |
Once-weekly exenatide versus once- or twice-daily insulin detemir: randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas.
Topics: Aged; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin Detemir; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2013 |
Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy.
Topics: Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Lipids; Male; Metformin; Middle Aged; Multivariate Analysis; Peptides; Prospective Studies; Treatment Outcome; Venoms | 2013 |
Randomized trial of continuous subcutaneous delivery of exenatide by ITCA 650 versus twice-daily exenatide injections in metformin-treated type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Peptides; Venoms; Young Adult | 2013 |
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Topics: Aged; Arginine; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; C-Peptide; Chimerin Proteins; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Exenatide; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Metformin; Middle Aged; Peptides; Resistin; Risk Factors; Serpins; Venoms | 2013 |
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Metformin; Middle Aged; Peptides; Postprandial Period; Receptors, Glucagon; Treatment Outcome; Venoms | 2014 |
Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
Topics: Adipokines; Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; Chi-Square Distribution; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Humans; Hypoglycemic Agents; Inflammation Mediators; Insulin; Insulin Resistance; Insulin-Secreting Cells; Intention to Treat Analysis; Italy; Lipids; Male; Metformin; Middle Aged; Peptides; Time Factors; Treatment Outcome; Venoms | 2013 |
Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Retrospective Studies; Venoms | 2013 |
Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Headache; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Nausea; Peptides; Sulfonylurea Compounds; Venoms; Vomiting | 2013 |
Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease.
Topics: Adiponectin; Adult; Aged; Alanine Transaminase; Blood Glucose; Body Mass Index; Body Weight; C-Reactive Protein; Diabetes Mellitus, Type 2; Exenatide; Fatty Liver; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Time Factors; Treatment Outcome; Venoms; Waist-Hip Ratio | 2013 |
Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptides; Humans; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Recombinant Fusion Proteins; Thiazolidinediones; Venoms | 2014 |
Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.
Topics: Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Lispro; Insulin, Long-Acting; Male; Meals; Metformin; Middle Aged; Peptides; Quality of Life; Receptors, Glucagon; Treatment Outcome; Venoms | 2014 |
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Thiazolidinediones; Venoms; Weight Gain; Weight Loss | 2015 |
Translating What Works: A New Approach to Improve Diabetes Management.
Topics: Aged; Algorithms; Blood Glucose; Decision Support Systems, Clinical; Diabetes Mellitus; Double-Blind Method; Exenatide; Female; Georgia; Glycated Hemoglobin; Hospitals, Veterans; Humans; Hypoglycemic Agents; Insulin; Internet; Male; Metformin; Middle Aged; Outpatients; Patient Care Team; Patient Education as Topic; Peptides; Primary Health Care; Program Development; Research Design; Sulfonylurea Compounds; Translational Research, Biomedical; United States; Venoms; Veterans | 2015 |
Treatment escalation options for patients with type 2 diabetes after failure of exenatide twice daily or glimepiride added to metformin: results from the prospective European Exenatide (EUREXA) study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Europe; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Peptides; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Failure; Venoms | 2015 |
Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes.
Topics: Albuminuria; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Postprandial Period; Risk Factors; Time Factors; Venoms | 2015 |
Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials.
Topics: Adult; Diabetes Mellitus; Double-Blind Method; Drug Administration Schedule; Exenatide; Female; Glucagon-Like Peptides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Male; Metformin; Middle Aged; Patient Satisfaction; Peptides; Recombinant Fusion Proteins; Surveys and Questionnaires; Time Factors; Venoms | 2015 |
Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study.
Topics: Aged; Biomarkers; Blood Glucose; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Europe; Exenatide; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Incretins; Lipids; Male; Metformin; Middle Aged; Peptides; Risk Factors; Sulfonylurea Compounds; Time Factors; Treatment Outcome; Venoms | 2015 |
Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
Topics: Adult; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Down-Regulation; Drug Therapy, Combination; Eating; Exenatide; Female; Ghrelin; Humans; Hypoglycemic Agents; Incretins; Metformin; Middle Aged; Obesity; Peptides; Postprandial Period; Prospective Studies; Time Factors; Treatment Outcome; Venoms; Weight Loss | 2016 |
Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.
Topics: Adult; Aged; Alanine Transaminase; Arrhythmias, Cardiac; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin, Short-Acting; Male; Meals; Metformin; Middle Aged; Peptides; Risk Factors; Serum Amyloid A Protein; Venoms | 2016 |
The effects of exenatide twice daily compared to insulin lispro added to basal insulin in Latin American patients with type 2 diabetes: A retrospective analysis of the 4B trial.
Topics: Adult; Aged; Argentina; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Insulin Lispro; Male; Metformin; Mexico; Middle Aged; Peptides; Retrospective Studies; Treatment Outcome; United States; Venoms | 2016 |
Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Heart Rate; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Treatment Outcome; Venoms | 2017 |
Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Topics: Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Drug Therapy, Combination; Excipients; Exenatide; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incidence; Incretins; Injections, Jet; Male; Metformin; Middle Aged; Peptides; Sitagliptin Phosphate; Triglycerides; United States; Venoms | 2017 |
Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus.
Topics: Adult; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Half-Life; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Male; Metformin; Middle Aged; Peptides; Postprandial Period; Venoms | 2017 |
Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Equipment Design; Exenatide; Female; Humans; Hypoglycemic Agents; Injections; Male; Metformin; Middle Aged; Patient Satisfaction; Surveys and Questionnaires; Young Adult | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study.
Topics: Anti-Obesity Agents; Benzhydryl Compounds; Blood Pressure; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Triglycerides | 2018 |
Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.
Topics: Adiposity; Adult; Aged; Blood Glucose; Body Fat Distribution; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Humans; Insulin Glargine; Insulin Resistance; Insulin, Long-Acting; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Obesity, Abdominal; Peptides; Venoms | 2018 |
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly alone, or dapagliflozin alone added to metformin monotherapy in subgroups of patients with type 2 diabetes in the DURATION-8 randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Middle Aged; Sodium-Glucose Transport Proteins | 2018 |
Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
Topics: Adipokines; Adult; Biomarkers; Blood Glucose; Carrier Proteins; Exenatide; Female; Glycoproteins; Humans; Hypoglycemic Agents; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome; Treatment Outcome | 2019 |
Olfactory Dysfunction Mediates Adiposity in Cognitive Impairment of Type 2 Diabetes: Insights From Clinical and Functional Neuroimaging Studies.
Topics: Adiposity; Adult; Aged; Blood Glucose; Brain; Cognition; Cognitive Dysfunction; Diabetes Mellitus, Type 2; Exenatide; Female; Functional Neuroimaging; Glucagon-Like Peptide-1 Receptor; Humans; Insulin; Liraglutide; Magnetic Resonance Imaging; Male; Metformin; Middle Aged; Obesity; Olfaction Disorders; Olfactory Perception; Smell | 2019 |
Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
Topics: Adult; Blood Glucose; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Generic; Equivalence Trials as Topic; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Injections; Insulin; Male; Metformin; Middle Aged; Secretagogues; Treatment Outcome | 2020 |
Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome; Young Adult | 2020 |
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
Topics: Adolescent; Adult; Blood Glucose; China; Drug Therapy, Combination; Exenatide; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Secretion; Metformin; Middle Aged; Obesity; Overweight; Polycystic Ovary Syndrome; Postprandial Period; Prediabetic State; Treatment Outcome; Young Adult | 2021 |
High baseline FGF21 levels are associated with poor glucose-lowering efficacy of exenatide in patients with type 2 diabetes.
Topics: Adult; Biomarkers, Pharmacological; Blood Glucose; China; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Fibroblast Growth Factors; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Treatment Outcome | 2021 |
Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-contr
Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Lipids; Liver Neoplasms; Metformin; Middle Aged; Pilot Projects; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
Exenatide Twice Daily Plus Glargine Versus Aspart 70/30 Twice Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Premixed Human Insulin and Metformin.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Insulin Glargine; Metformin | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Obesity; Phentermine; Polycystic Ovary Syndrome; Prospective Studies; Single-Blind Method; Topiramate; Treatment Outcome; Weight Loss; Young Adult | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Once-Weekly Exenatide in Youth With Type 2 Diabetes.
Topics: Adolescent; Blood Glucose; Child; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Peptides; Venoms | 2022 |
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Fibroblast Growth Factors; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2022 |
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Topics: Exenatide; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Weight Loss | 2022 |
74 other study(ies) available for metformin and exenatide
| Article | Year |
|---|---|
Drugs for diabetes.
Topics: Acarbose; Chromans; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Insulin; Metformin; Peptides; Thiazolidinediones; Troglitazone; Venoms | 2005 |
Exenatide.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Molecular Sequence Data; Peptides; Sulfonylurea Compounds; Venoms | 2005 |
[Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].
Topics: Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Islets of Langerhans; Metformin; Peptides; Placebos; Time Factors; Venoms; Weight Loss | 2005 |
Incretin mimetics as a novel therapeutic option for hepatic steatosis.
Topics: Diabetes Mellitus, Type 2; Exenatide; Fatty Liver; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Venoms | 2006 |
[Improved blood sugar control plus weight loss].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Peptides; Sulfonylurea Compounds; Time Factors; Venoms; Weight Loss | 2006 |
Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50
Topics: Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Metformin; Peptides; Research Design; Sulfonylurea Compounds; Venoms | 2007 |
Summaries for patients. Exenatide therapy for type 2 diabetes.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Male; Metformin; Middle Aged; Nausea; Peptides; Thiazolidinediones; Venoms; Vomiting; Weight Loss | 2007 |
Exenatide in combination therapy: small study, big market, and many unanswered questions.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Research Design; Thiazolidinediones; Venoms | 2007 |
[New class of oral antidiabetic drugs. Effective in combination with metformin].
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Treatment of type 2 diabetes mellitus and the incretin system.
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles; United States; Venoms | 2007 |
New medications help those with diabetes avoid heart trouble. Drugs mimic the body's natural insulin and glucose controls, but diet and exercise are still keys to controlling the disease.
Topics: Diabetes Mellitus; Diabetic Angiopathies; Exenatide; Heart Diseases; Humans; Hypoglycemic Agents; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms | 2007 |
Type 2 diabetes: the end of clinical inertia.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Nebulizers and Vaporizers; Peptides; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2007 |
[New data on hypoglycemia risk and beta cell function].
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Metformin; Peptides; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Venoms; Weight Gain; Weight Loss | 2007 |
Clinical decisions. Management of type 2 diabetes--polling results.
Topics: Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glipizide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin, Isophane; Metformin; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2008 |
Is exenatide improving the treatment of type 2 diabetes? Analysis of the individual clinical trials with exenatide.
Topics: Animals; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Sulfonylurea Compounds; Venoms | 2007 |
[Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
Topics: Diabetes Mellitus, Type 2; Diet, Diabetic; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Insulin; Metformin; Patient Education as Topic; Patient Selection; Peptides; Venoms | 2008 |
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide.
Topics: Adolescent; Adult; Databases, Factual; Exenatide; Female; Glyburide; Humans; Hypoglycemic Agents; Insurance, Health; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Pyrazines; Risk Assessment; Safety; Sitagliptin Phosphate; Triazoles; United States; Venoms; Young Adult | 2009 |
Exenatide and acute pancreatitis.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Drug Interactions; Exenatide; Female; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Middle Aged; Pancreatitis; Peptides; Sulfonylurea Compounds; Venoms | 2008 |
Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Multicenter Studies as Topic; Peptides; Randomized Controlled Trials as Topic; Reproducibility of Results; Risk Assessment; Sulfonylurea Compounds; Venoms | 2009 |
The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Sulfonylurea Compounds; Venoms; Young Adult | 2009 |
[Insulin secretion is increased depending on glucose.. Metabolism regulation in type 2 diabetes mellitus over five paths].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucose; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Peptides; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Weight Loss | 2009 |
New therapeutic options: management strategies to optimize glycemic control.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Life Style; Male; Metformin; Middle Aged; Peptides; Pyrazines; Risk Factors; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
[Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Topics: Blood Glucose; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Exercise; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Recurrence; Venoms | 2010 |
Individualised incretin-based treatment for type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Introduction.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
Remission of diabetes mellitus type 2 with severe hyperglycemia after Exenatide treatment.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Metformin; Middle Aged; Obesity; Peptides; Remission Induction; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Venoms; Weight Loss | 2010 |
Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Topics: Aged; Body Weight; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Pioglitazone; Thiazolidinediones; Venoms | 2011 |
Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
Topics: Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Male; Metformin; Middle Aged; Models, Econometric; Peptides; Quality-Adjusted Life Years; Statistics, Nonparametric; Sulfonylurea Compounds; United States; Venoms | 2010 |
Pharmacotherapy: GLP-1 analogues and insulin: sound the wedding bells?
Topics: Animals; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Peptides; Pioglitazone; Randomized Controlled Trials as Topic; Thiazolidinediones; Venoms | 2011 |
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Carbamates; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; HIV Infections; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Peptides; Piperidines; Venoms; Waist Circumference; Weight Loss | 2011 |
Exendin-4 upregulates the expression of Wnt-4, a novel regulator of pancreatic β-cell proliferation.
Topics: Animals; Cell Proliferation; Cells, Cultured; Drug Evaluation, Preclinical; Exenatide; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Glucose; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Metformin; Mice; Mice, Inbred C57BL; Peptides; Receptors, Glucagon; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Tolbutamide; Up-Regulation; Venoms; Wnt4 Protein | 2011 |
Incretin-based therapy and the quest for sustained improvements in β-cell health.
Topics: Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Peptides; Venoms | 2011 |
[Rare cause of insufficient metabolic control of diabetes mellitus - Case 10/2011].
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocorticotropic Hormone; Cushing Syndrome; Diabetes Mellitus, Type 2; Exenatide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptides; Pheochromocytoma; Tomography, Emission-Computed, Single-Photon; Venoms | 2011 |
Drug treatment of obesity.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms | 2011 |
Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.
Topics: Animals; Exenatide; Glucagon-Like Peptide-1 Receptor; Homeodomain Proteins; Humans; Hypoglycemic Agents; Male; Metformin; Mice; Mutation; Pancreatic Ducts; Pancreatitis; Peptides; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; Receptors, Glucagon; Trans-Activators; Venoms | 2012 |
Incretin-based therapies in clinical practice: from efficacy to effectiveness. Focus on liraglutide.
Topics: Aged; Body Mass Index; Dipeptidyl Peptidase 4; Drug Monitoring; Drug Therapy, Combination; Exenatide; Female; Follow-Up Studies; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Male; Metformin; Middle Aged; Outpatient Clinics, Hospital; Patient Acceptance of Health Care; Peptides; Retrospective Studies; Treatment Outcome; Venoms | 2012 |
The role of combination therapy in type 2 diabetes in the post-ACCORD era.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Drug Therapy, Combination; Evidence-Based Medicine; Exenatide; Female; Humans; Hypertension; Hypoglycemic Agents; Male; Metformin; Peptides; Venoms | 2012 |
Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Administration Schedule; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Medication Adherence; Metformin; Middle Aged; Peptides; Risk Factors; Sulfonylurea Compounds; Time Factors; Venoms; Weight Gain | 2013 |
Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Exenatide; Feeding Behavior; Fenofibrate; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Glucose Tolerance Test; Homeostasis; Immunohistochemistry; Injections, Intraperitoneal; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Peptides; Rats; Receptors, Glucagon; Venoms | 2013 |
Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
Topics: Blood Glucose; Carbamates; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Fasting; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Metformin; Middle Aged; Peptides; Piperidines; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Failure; Triazoles; Venoms | 2014 |
Efficacy of laparoscopic sleeve gastrectomy and intensive medical management in obese patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gastrectomy; Humans; Hypertension; Hypoglycemic Agents; Insulin Detemir; Insulin, Long-Acting; Laparoscopy; Male; Metformin; Middle Aged; Peptides; Quality of Life; Treatment Outcome; Venoms; Young Adult | 2014 |
Correlated increase of omentin-1 and adiponectin by exenatide, avandamet and dietary change in diet-induced obese rats.
Topics: Adiponectin; Animals; Cytokines; Drug Combinations; Exenatide; Metformin; Obesity; Peptides; Rats; Thiazoles; Venoms | 2013 |
GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK.
Topics: Adipose Tissue, Brown; Adult; Aged; Aged, 80 and over; AMP-Activated Protein Kinase Kinases; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Eating; Energy Metabolism; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Hypothalamus; Liraglutide; Male; Metformin; Mice; Middle Aged; Obesity; Peptides; Protein Kinases; Rats; Thermogenesis; Venoms; Young Adult | 2014 |
Effective weight loss after treatment with a glucagon-like peptide-1 receptor agonist in a morbidly obese and diabetic patient before bariatric surgery: a case report.
Topics: Adult; Bariatric Surgery; Combined Modality Therapy; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Metformin; Obesity, Morbid; Peptides; Preoperative Care; Receptors, Glucagon; Venoms; Weight Loss | 2014 |
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry.
Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin | 2014 |
Is insulin the most effective injectable antihyperglycaemic therapy?
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Exenatide; Fasting; Female; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Male; Metformin; Middle Aged; Peptides; Treatment Outcome; Venoms | 2015 |
Use of the analytic hierarchy process for medication decision-making in type 2 diabetes.
Topics: Decision Making; Decision Support Techniques; Diabetes Mellitus, Type 2; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Peptides; Venoms | 2015 |
Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Exenatide; Female; Gene Expression Regulation, Enzymologic; Immunohistochemistry; Metformin; Ovary; Peptides; Polycystic Ovary Syndrome; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Sirtuin 1; Up-Regulation; Venoms | 2015 |
Combined Treatment with Exendin-4 and Metformin Attenuates Prostate Cancer Growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Humans; Male; Metformin; Mice; Mice, Nude; Peptides; Phosphorylation; Prostatic Neoplasms; Venoms | 2015 |
Effects of Exenatide on Metabolic Changes, Sexual Hormones, Inflammatory Cytokines, Adipokines, and Weight Change in a DHEA-Treated Rat Model.
Topics: Adipokines; Animals; Body Weight; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; Exenatide; Female; Gonadal Steroid Hormones; Inflammation Mediators; Metformin; Ovary; Peptides; Polycystic Ovary Syndrome; Rats; Rats, Sprague-Dawley; Venoms | 2016 |
Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Lipids; Liraglutide; Liver Function Tests; Male; Metabolic Syndrome; Metformin; Middle Aged; Non-alcoholic Fatty Liver Disease; Peptides; Pilot Projects; Pioglitazone; Prospective Studies; Sitagliptin Phosphate; Thiazolidinediones; Venoms; Waist Circumference | 2016 |
Effects of addition of a dipeptidyl peptidase IV inhibitor to metformin on sirolimus-induced diabetes mellitus.
Topics: Animals; Apoptosis; Cell Survival; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Drug Therapy, Combination; Exenatide; Hyperglycemia; Islets of Langerhans; Male; Metformin; Mitochondria; Oxidative Stress; Peptides; Piperidones; Pyrimidines; Rats, Sprague-Dawley; Reactive Oxygen Species; Sirolimus; Venoms | 2016 |
Long-Term Effectiveness and Cost-Effectiveness of Metformin Combined with Liraglutide or Exenatide for Type 2 Diabetes Mellitus Based on the CORE Diabetes Model Study.
Topics: Adult; Asian People; China; Computer Simulation; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Life Expectancy; Liraglutide; Male; Metformin; Middle Aged; Peptides; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome; Venoms | 2016 |
Exenatide and metformin express their anti-inflammatory effects on human monocytes/macrophages by the attenuation of MAPKs and NFκB signaling.
Topics: Adolescent; Adult; AMP-Activated Protein Kinases; Anti-Inflammatory Agents; CCAAT-Enhancer-Binding Protein-beta; Cells, Cultured; Chemokine CCL2; Enzyme Activation; Exenatide; Humans; Inflammation Mediators; Macrophages; Metformin; Mitogen-Activated Protein Kinases; Monocytes; NF-kappa B; Oxidative Stress; Peptides; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha; Venoms; Young Adult | 2016 |
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.
Topics: Acute Disease; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin Glargine; Male; Metformin; Middle Aged; Pancreatitis; Peptides; Recombinant Fusion Proteins; Sitagliptin Phosphate; Venoms | 2017 |
Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
Topics: Adult; Anti-Obesity Agents; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Sexual Dysfunction, Physiological; Sulfonylurea Compounds; Testosterone; Treatment Outcome | 2018 |
Hyperglycemia induces NF-κB activation and MCP-1 expression via downregulating GLP-1R expression in rat mesangial cells: inhibition by metformin.
Topics: Animals; Cell Line; Chemokine CCL2; Diabetic Nephropathies; Exenatide; Glucagon-Like Peptide-1 Receptor; Glucose; Hyperglycemia; Mesangial Cells; Metformin; Mice; NF-kappa B | 2019 |
Dipeptidyl peptidase-4 inhibitors do not alter GH/IGF-I axis in adult diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Human Growth Hormone; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor I; Liraglutide; Male; Metformin; Middle Aged | 2020 |
Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
Topics: AMP-Activated Protein Kinases; Androgens; Animals; Blood Glucose; Disease Models, Animal; Exenatide; Female; Gene Expression Regulation; Humans; Insulin Resistance; Luteinizing Hormone; Metformin; Polycystic Ovary Syndrome; Rats; Sirtuin 1 | 2019 |
Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near-normoglycaemia.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Life Style; Metformin; Venoms | 2020 |
Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Progression; Dose-Response Relationship, Drug; Exenatide; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Metformin; NF-kappa B; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Signal Transduction; Toll-Like Receptor 4 | 2020 |
Metformin, resveratrol, and exendin-4 inhibit high phosphate-induced vascular calcification via AMPK-RANKL signaling.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Enzyme Activators; Exenatide; Metformin; Muscle, Smooth, Vascular; Phosphates; RANK Ligand; Rats; Resveratrol; Signal Transduction; Vascular Calcification | 2020 |
The role of nursing care in the type 2 diabetes treatment associated with chronic liver diseases.
Topics: Diabetes Mellitus, Type 2; Exenatide; Gliclazide; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Sitagliptin Phosphate | 2022 |
Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats.
Topics: Animals; Body Weight; Estrous Cycle; Exenatide; Female; Glucose Tolerance Test; Hepatocyte Nuclear Factor 4; Insulin Resistance; Liver; Metformin; Phosphatidylinositol 3-Kinases; Polycystic Ovary Syndrome; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Sex Hormone-Binding Globulin; Triglycerides; Up-Regulation | 2021 |
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Topics: Diabetes Mellitus, Type 2; Exenatide; Humans; Liver; Liver Cirrhosis; Metformin; Non-alcoholic Fatty Liver Disease; Pioglitazone; Prevalence | 2022 |
The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Exenatide; Insulin Receptor Substrate Proteins; Insulin Resistance; Liver; Male; Metformin; Non-alcoholic Fatty Liver Disease; Obesity; Pioglitazone; Rats; Rats, Wistar | 2022 |
The glucose tolerance test in mice: Sex, drugs and protocol.
Topics: Adult; Animals; Blood Glucose; Exenatide; Female; Glucose; Glucose Tolerance Test; Humans; Male; Metformin; Mice; Mice, Inbred C57BL | 2022 |
Effects of antidiabetics and exercise therapy on suppressors of cytokine signaling-1, suppressors of cytokine signaling-3, and insulin receptor substrate-1 molecules in diabetes and obesity.
Topics: Animals; Cytokines; Diabetes Mellitus, Experimental; Exenatide; Exercise Therapy; Humans; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Metformin; Obesity; Rats; Rats, Wistar; Suppressor of Cytokine Signaling Proteins | 2023 |
Comparison of the Impact of SGLT2-Inhibitors and Exenatide on Body Fat Composition.
Topics: Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Exenatide; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone.
Topics: Exenatide; Female; Gastrointestinal Microbiome; Humans; Metagenomics; Metformin; Obesity; Polycystic Ovary Syndrome | 2023 |